KHK 4083

Drug Profile

KHK 4083

Alternative Names: KHK4083

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Kyowa Hakko Kirin
  • Class Antibodies
  • Mechanism of Action Immunomodulators; OX40 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • No development reported Autoimmune disorders

Most Recent Events

  • 05 Dec 2016 Kyowa Hakko Kirin Pharma plans a phase I trial for Ulcerative colitis in Japan (IV and SC) (NCT02985593)
  • 28 Nov 2016 Investigation in Ulcerative colitis in Japan (SC)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Autoimmune-disorders in Canada (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top